What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Internal medicine, Melanoma, Oncology, Cancer and Cancer research.
His research integrates issues of Immune system, Immunotherapy, Biopsy and Drug resistance in his study of Melanoma.
His Oncology research is multidisciplinary, relying on both Antibody, Dabrafenib and Neuroblastoma RAS viral oncogene homolog.
His research investigates the connection with Cancer and areas like Biomarker which intersect with concerns in Tumor-infiltrating lymphocytes and Carcinoma.
His biological study spans a wide range of topics, including Anti pd 1, Toxicity and MAPK/ERK pathway.
Douglas B. Johnson has researched Ipilimumab in several fields, including CTLA-4 and Nivolumab.
His most cited work include:
- Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma (1334 citations)
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade (826 citations)
- Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (635 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Melanoma, Internal medicine, Cancer research, Oncology and Cancer.
His studies deal with areas such as Immunology, Immune system, Immunotherapy, Targeted therapy and Neuroblastoma RAS viral oncogene homolog as well as Melanoma.
In general Internal medicine study, his work on Ipilimumab, Adverse effect and Pembrolizumab often relates to the realm of In patient, thereby connecting several areas of interest.
His work carried out in the field of Ipilimumab brings together such families of science as Nivolumab, Clinical trial and Surgery.
His research in Cancer research intersects with topics in Immune checkpoint, Trametinib, MAPK/ERK pathway and Mutation.
His Cancer research includes themes of Bioinformatics, Intensive care medicine, Antibody, Biomarker and Fulminant.
He most often published in these fields:
- Melanoma (45.72%)
- Internal medicine (44.25%)
- Cancer research (35.10%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (44.25%)
- Melanoma (45.72%)
- Cancer (22.42%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Melanoma, Cancer, Adverse effect and Oncology.
His research in the fields of Ipilimumab, Nivolumab and Retrospective cohort study overlaps with other disciplines such as In patient.
His Melanoma study is concerned with the larger field of Cancer research.
Douglas B. Johnson combines subjects such as Fulminant, Disease, Immune system and Intensive care medicine with his study of Cancer.
Douglas B. Johnson has included themes like Discontinuation, Myocarditis, Incidence, Pneumonitis and Immunotherapy in his Adverse effect study.
His study looks at the relationship between Oncology and topics such as Clinical endpoint, which overlap with Trametinib, Cohort study and Cohort.
Between 2019 and 2021, his most popular works were:
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
- Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study (59 citations)
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease (38 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Adverse effect, Melanoma, Cancer and In patient.
His Internal medicine research incorporates elements of Gastroenterology and Oncology.
His Adverse effect research integrates issues from Body mass index and Myocarditis.
Melanoma is the subject of his research, which falls under Cancer research.
His study in Cancer research is interdisciplinary in nature, drawing from both Targeted therapy, CDKN2A, Growth inhibition, Neuroblastoma RAS viral oncogene homolog and PTEN.
His work deals with themes such as Quality of life, Blood pressure, Renal cell carcinoma, Lung cancer and Type 2 diabetes, which intersect with Cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
